Literature DB >> 29417402

Cost Effectiveness of Routine Laryngoscopy in the Surgical Treatment of Differentiated Thyroid Cancer.

Kyle Zanocco1, David J Kaltman2, James X Wu3, Abbey Fingeret4, Keith S Heller5, James A Lee6, Michael W Yeh3, Julie Ann Sosa7, Cord Sturgeon2.   

Abstract

BACKGROUND: Some surgeons perform flexible fiberoptic laryngoscopy (FFL) in all patients prior to thyroid cancer operations. Given the low likelihood of recurrent laryngeal nerve (RLN) or aerodigestive invasion in clinically low-risk thyroid cancers, the value of routine FFL in this group is controversial. We hypothesized that routine preoperative FFL would not be cost effective in low-risk differentiated thyroid cancer (DTC).
METHODS: A decision model was constructed comparing preoperative FFL versus surgery without FFL in a clinical stage T2 N0 DTC patient without voice symptoms. Total thyroidectomy and definitive hemithyroidectomy were both modeled as possible initial surgical approaches. Outcome probabilities and their corresponding utilities were estimated via literature review, and costs were estimated using Medicare reimbursement data. Sensitivity analysis was conducted to examine the uncertainty of cost, probability, and utility estimates in the model.
RESULTS: When the initial surgical strategy was total thyroidectomy, routine preoperative FFL produced an incremental cost of $183 and an incremental effectiveness of 0.000126 quality-adjusted life-years (QALYs). The incremental cost-effectiveness ratio (ICER) for routine FFL prior to total thyroidectomy was $1.45 million/QALY, exceeding the $100,000/QALY threshold for cost effectiveness. Routine FFL became cost effective if the preoperative probability of asymptomatic vocal cord paralysis increased from 1.0% to 4.9%, or if the cost of preoperative FFL decreased from $128 to $27. Changing the extent of initial surgery to hemithyroidectomy produced a higher ICER for routine FFL of $1.7 million/QALY.
CONCLUSION: Routine preoperative FFL is not cost effective in asymptomatic patients with sonographically low-risk DTC, regardless of the initial planned extent of surgery.

Entities:  

Mesh:

Year:  2018        PMID: 29417402     DOI: 10.1245/s10434-018-6356-2

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  3 in total

1.  Association of Hypocalcemia and Magnesium Disorders With Thyroidectomy in Commercially Insured Patients.

Authors:  Rui Han Liu; Christopher R Razavi; Hsien-Yen Chang; Ralph P Tufano; David W Eisele; Christine G Gourin; Jonathon O Russell
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2020-03-01       Impact factor: 6.223

2.  Thyroidectomy for thyroid cancer via transareola single-site endoscopic approach: results of a case-match study with large-scale population.

Authors:  Juyong Liang; Ling Zhan; Ming Xuan; Qiwu Zhao; Lingxie Chen; Jiqi Yan; Jie Kuang; Jian Tan; Weihua Qiu
Journal:  Surg Endosc       Date:  2021-03-29       Impact factor: 4.584

3.  Care and Management of Voice Change in Thyroid Surgery: Korean Society of Laryngology, Phoniatrics and Logopedics Clinical Practice Guideline.

Authors:  Chang Hwan Ryu; Seung Jin Lee; Jae-Gu Cho; Ik Joon Choi; Yoon Seok Choi; Yong Tae Hong; Soo Yeon Jung; Ji Won Kim; Doh Young Lee; Dong Kun Lee; GIljoon Lee; Sang Joon Lee; Young Chan Lee; Yong Sang Lee; Inn Chul Nam; Ki Nam Park; Young Min Park; Eui-Suk Sung; Hee Young Son; In Hyo Seo; Byung-Joo Lee; Jae-Yol Lim
Journal:  Clin Exp Otorhinolaryngol       Date:  2021-06-01       Impact factor: 3.372

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.